Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Gilead, J & J Working on HIV Pills

By Drug Discovery Trends Editor | June 28, 2011

NEW YORK (AP) – Gilead Sciences Inc. and a unit of Johnson & Johnson say they plan to work together to develop a pair of combination HIV pills.

The companies said they have agreed to collaborate on a pill that combines Johnson & Johnson’s HIV drug Prezista with Gilead’s drug candidate cobicistat, which is designed to make other anti-retroviral drugs more effective. They are negotiating a collaboration that would create a drug combining Prezista with Gilead’s HIV drug Emtriva, along with another Gilead drug candidate called GS 7340. GS 7340 is a version of Gilead’s older drug Viread.

The deal won’t be completed unless the companies come to an agreement on the second combination pill. The companies did not disclose financial terms of the potential partnership, which would be between Gilead and Tibotec Pharmaceuticals, a unit of Johnson & Johnson’s Ortho Biotech Inc.

Tibotec would be responsible for formulating the first pill as well as for manufacturing, regulatory matters, and sales worldwide, while Gilead would be responsible for development and sales of the second product. Gilead retains all rights to cobicistat as a standalone product and for use with other drugs.

Date: June 28, 2011
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50